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Investigation of altered resistance of laboratory
animals to the systemic mycoses has centered
largely on eoccidioidomycosis (1, 2), and histo-
plasmosis (3, 4). The lack of a dependable non-
toxic chemotherapeutic agent, and the high inci-
dence of these two diseases have undoubtedly
influenced research on them. Sporotrichosis, on
the other hand, can be treated effectively with
potassium iodide, although treatment must be
extended over several months to insure cure. The
incidence of this infection is not as high as that
of coccidioidomycosis or histoplasmosis,but under
some circumstances it has caused very large
epidemics (5).
The early studies of Jessner (6) with sporo-
trichosis in rats indicated that a partial immunity
existed to cutaneous reinfection. Kesten and
Martenstein (7) reported that, after intracardial
injection of Sporotrichum schenckii spores, blood
cultures were sterile earlier in animals with pre-
vious experimental cutaneous sporotrichosis than
in animals without previous exposure to the
fungus.
This paper reports results obtained from
attempts to increase the resistance of Swiss white
mice to sporotrichosis.
MATERIALS AND METHODS
Strain and Cultural Procedures
The strain of 8. schenckii used throughout this
study was isolated from a case of human sporotri-
chosis. Yeast-like growth of this organism from
blood glucose cysteine agar, incubated 4 days at
370 C. was used for the preparation of the various
vaccines, or for challenge. Conidiospore suspen-
sions for rabbit immunization were prepared from
8. .schenckii cultures grown on modifiedf Sabou-
raud's agar slants incubated at 300 C. for 7 days.
Cultures from tissues were made by removing
the spleen and a portion of the liver aseptically
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t Difco neopeptone 1%, dextrose 2%, agar 2%,
pH 6.8.
from chloroformed animals, maccrating them on
Sabouraud's agar slants, and incubating for two
weeks at 30° C. Four slants were inoculated per
animal, i.e., 2 slants from spleen and 2 from liver.
Vaccines
The vaccine preparations were of 4 general
categories: 1. nonviable suspensions of S. schenckii
yeast-like cells; 2. an acetone extract of the yeast-
like cells; 3. saline extracts or homogenates from
8. schenckii infected mouse spleens; and 4. viable
suspensions of S. schenckii.
Three nonviable vaccines were prepared as
follows: 1. Yeast cells were suspended in a 2%
formalin solution at 370 C. for 48 hours and sub-
sequently washed several times with sterile physi-
ological saline; 2. 8. schenckii cells were left over-
night in acetone at 4° C.then washed with saline;
and 3. yeast-like cells were suspended at 55° C.
for 40 minutes and washed. These vaccines were
proved to be sterile by culturing, and were used
after appropriate dilution.
The tissue extracts and homogenates were pre-
pared from the spleens of mice infected intra-
venously with 8. schenckii by grinding in a sterile
mortar at a spleen-saline ratio of 1:4 weight!
volume. Pour plates made in triplicate with ten-
fold dilutions of infected splenic tissue indicated
that there were approximately 13.3 X 106 viable
8. schenckii cells per 0.1 gram. The homogenate
was heated for an hour at 55° C.; the coarse tissue
particles were allowed to settle for 15 minutes,
and the supernatant was removed and tested as an
immunizing agent. The extract was obtained by
the centrifugation of unheated ground spleen-
saline mixture, followed by Seitz filtration as a
means of sterilization. Control extracts and
homogenates were made from spleens of normal
mice following the same procedure. Cultures from
these preparations produced no growth when
tested for sterility.
The acetone extract of yeast-like cells of S.
schenckii was produced by treating the 4-day
growth from 6 blood glucose cystine agar slants
with 20 ml. of acetone overnight at 40 C. The
acetone was decanted from the yeast-like cells
and evaporated on an electric plate set at low
temperature. The material remaining after evapo-
ration was reconstituted with 20 ml. of saline,
filtered through a Seitz filter, and after dilution
tested as an immunizing agent.
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Animals
Female Swiss white mice weighing 17—19 grams,
and obtained from the Animal Production Section
of the National Institutes of Health, were used
for this investigation.
Male albino rabbits weighing 2.5—3 kilograms,
from the above-mentioned source, were utilized
for the production of S. schenckii antiserum.
Immunization Procedures
Two rabbits were immunized with viable yeast-
cell suspensions of S. schenckii and two with
viable cunidiospore preparations. Ten injections
of the cells or spores were given intravenously at
5-day intervals with initial doses of approxi-
mately 5 X 10 cells, and increasing to approxi-
mately 3 X 1ff' cells at the final administration.
The immunizing suspensions were freshly made up
for each injection. The animals were test bled 12
days after completion of the schedule for immuni-
zation. Agglutination titers of the immune sera
ranged from dilutions of 1:1280 to 1:5120, while
the preimmunization sera showed no agglutination
at 1:20. Cross-agglutination with yeast cells and
conidiospores between the homologous and heter-
ologous sera demonstrated no apparent differ-
ences. Immune serum from the blood of these
rabbits was used for subsequent passive immuni-
zation experiments.
Serum from mice with chronic infections of 10
weeks was collected and used f or passive immuni-
zation studies. It showed an agglutination titer of
1:160, whereas, normal mouse serum had no ag-
glutinating titer at 1:20.
For active immunization of mice with killed
antigens, the heated S. schenckii cells, formalin-
treated, or acetone-treated suspensions were
injected intra-abdominally every 3 days. Five
doses were giyep starting with 2.5 X 10 cells in
the first injection and increasing to 15 X 106 cells
in the final injection. The control groups received
sterile saline injections on the same schedule.
Seven days after the immunization schedule had
been completed, the animals were challenged.
Mice receiving the saline-reconstituted acetone
extract of S. schenckii yeast-like cells were in-
jected every third day for a total of 5 injections.
The dose was increased each time as follows: they
first received 0.1 ml. of the 1:100 dilution, then
0.2 ml. and 0.3 ml. of the 1:100 dilution, followed
by 0.1 and 0.2 ml. of the 1:10 dilution. Seven days
after the fifth injection, they were challenged.
Animals receiving the heated homogenates of
infected spleens, and non-heated extracts were
given 0.1 ml. of a 1:10 dilution of the original
homogenate or extract intra-abdominally every
fifth day. Five injections were given. Controls
were treated with normal spleen homogenates or
extracts, or saline in a comparable fashion.
For the superinfection studies, mice were in-
jected intra-abdominally with 5 X 10 viable S.
schenckii yeast-like cells. Three groups were in-
fected; one 3 weeks before challenge, another 2
weeks before, and the third group 1 week previous
to challenge. Control groups for each time interval
were given 5 X 10 heat-killed S. sckenckii cells.
One untreated control group was included in the
study.
Sera from the immune rabbits, normal rabbits,
infected mice, and normal mice were heated at 56°
C. for 30 minutes and diluted 1:20. One tenth ml.
was given intra-abdominally to the proper group
of mice 24 hours before challenge, 3 hours after,
and every other day until the experiment was
terminated. The saline controls were injected
similarly.
Quantitation of Challenging Doses and
Whole Cell Vaccines
The number of S. schenckii yeast-like cells for
challenging purposes, and immunizing doses of
whole-cell vaccines, was determined by direct
count in a Levy hemoeytometer counting chamber.
Tenfold dilutions in sterile 0.85% NnCl solution
were made and 0.2 ml. of the appropriate dilution
was injected intravenously into the tail vein of
the experimental mouse. Thermal dilatation of
the veins of the test animals facilitated injection.
Criterion for Interpretation of Results
The endpoint utilized for evaluation of the
results being reported was death of the test ani-
mals. Mice injected intravenously with S.
schenckii cells died at a uniform rate ranging from
10 days to 5 weeks depending upon the size of the
challenging dose. The survivors were infected
and these data represent a comparison of sur-
vivor numbers and deaths. All experiments, unless
otherwise indicated, were terminated 2 months
after challenge.
EXPEEJMENTAL EESULT5
Non-Viable Suspensions of Yeast-Like Cells
The data obtained from mice injected with
heat-killed suspensions of S. schenckii yeast-like
cells, and subsequently challenged with viable
suspensions, are presented in Table 1. It is obvi-
ous that no protection was demonstrated in the
treated animals.
The effects of immunization with acetone or
formalin-treated antigens are shown in Table 2.
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Under the circumstances of this experiment, it
appears that the formalin-treated suspensions
conferred some protection to the recipient mice.
The animals that survived the experimental
period of 8 weeks were closely observed at the
termination of the experiment. Cultures were
made from the livers and spleens of only those
groups receiving 3.8 x 102 cells, and since all the
other survivors demonstrated external lesions due
to sporotrichosis, they were not examined. The
livers and spleens of mice receiving the acetone-
treated suspension were covered with abscesses
and were heavily positive by culture. Cultures
were positive from 2 of 5 animals from the group
TABLE 1
Deaths of mice vaccinated with heat-killed
S. schenckii, after challenge
Vaccine
Challenging Dose
2.2 X 106 2.2 X 10 2.2 X l0 2.2 X jQ3 2.2 X 10
Heated 5/5 5/5 1/5 0/5 0/5
cells
Saline 4/5 5/5 2/5 0/5 0/5
Numerator indicates number of deaths; de-
nominator indicates number of challenged.
TABLE 2
Deaths of mice vaccinated with an acetone-treated
suspension or formalinized suspension of
S. schenckii, after challenge
Vaccine
Challenging Dose
3.8 X 3.8 X 3.8 X 3.8 X 3.8 X
108 jØb 10 10 102
Acetone treated 4/5 5/5 2/5 0/5 0/5
Formalin treated 2/5 0/5 0/5 1/5 0/5
Saline 5/5 3/5 2/5 0/5 0/5
Numerator indicates number of deaths; de-
nominator indicates number of challenged.
immunized with the formalin-treated suspension,
while only 1 of the saline controls was positive.
These results suggest that although the death
rate was reduced in mice receiving the formalin-
treated vaccine, the survivors possessed no appar-
ent superiority in eliminating the infection.
Since the results obtained from the immuni-
zation of mice with formalin-treated S. schenckii
cells were encouraging, another experiment was
employed to evaluate the level of immunity in
another manner. Separate groups of mice were
immunized with a formalin-killed vaccine,
acetone-killed cells, the acetone extract from
acetone-treated cells, and a control group was
injected with saline. After the immunizing schedule
was completed, each animal was challenged with
106 S. schenckii cells. The data from this experi-
ment are shown in Table 3. Under the conditions
of this experiment, the level of protection in the
group of mice immunized with the formalinized
suspension was not as high as expected.
Spleen Homogenates and Extracts
Table 4 presents the results from the immuni-
zation of mice with heated homogenates of spleens
from infected or normal animals. Very little dif-
ference can be observed between the test and
control groups. Similar results were obtained
using unheated, filtered extracts as shown in
Table 5.
Superinfections
The survivor rate was slightly greater in the
previously infected groups than in normal mice
or those that received the heated yeast-like sus-
pension. The results are presented in Table 6.
The length of the initial infection seemed to have
little effect upon the survivor rate after challenge.
Passive Immunization
Even though the sera were injected over a
period of 8 weeks, no protection was observed in
TABLE 3
Deaths of vaccinated mice after challenge with approximately 106 cells S. schenckii
Formalin Treated Vaccine Acetone Treated Vaccine Acetone Extract Saline
Deaths % Survivors Deaths % Survivors Deaths % Survivors Deaths % Survivors
39/50 22 45/48 6.2 42.48 12.5 43/50 14
Numerator indicates number of deaths; denominator indicates number challenged.
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the groups that received either the immune rab-
bit serum, or the serum from chronically infected
mice (Table 7). No apparent evidence of hyper-
sensitive complications appeared in the surviving
mice that received the rabbit serum.
All of the experiments presented in this paper,
with one exception, have been repeated with sim-
ilar results. The exception is the study of immuni-
zation with unheated splenic extracts.
It is of interest to note that in the groups of
mice which received the acetone-treated 8.
schenckii cell suspension, there was a slight tend-
ency for more susceptibility. This tendency was
not manifested by a greater death rate, as shown
in Table 2, but by more frequent recovery of the
TABLE 4
Deaths in mice vaccinated with homogenates
of heated infected spleens or homogenates
of heated normal spleens, after challenge"
7X
10'
7X
10'
7X
104
lx
103
7X
10'
Homogenate of in-
fected spleen ..... 5/5 5/5 4/5 0/5 0/5
Homogenate of nor-
mal spleen 5/5 5/5 4/4 2/5 0/5
Saline 5/5 4/5 5/5 2/5 0/5
* Experiment terminated 6 weeks after chal-
lenge.
Numerator indicates number of deaths; de-
nominator indicates number challenged.
TABLE 5
Deaths in mice vaccinated with filtered extracts of
infected spleens or filtered extracts of normal
spleens, after challenge"
Vaccine
1.9 X
106
1.9 X
10'
1.9 X
10'
1.9 X
10'
1.9 X
102
Extract of infected
spleen
Extract of normal
spleen
Saline
5/5
5/5
5/5
5/5
5/5
5/5
2/5
3/5
5/5
0/5
0/5
0/5
0/5
0/5
0/5
lenge.
Numerator indicates number of deaths; de-
nominator indicates number challenged.
Challenging Dose
TABLE 6
Deaths of mice with preinfection. or a single injection.
of heated vaccine, after challenge
Length of Infection or Time of
Vaccination Before Challenge
Challenging Dose
9
x
9
x
9
X
,9
x
9
x
Infected 3 weeks
Vaccinated 3 weeks. .. .
Infected 2 weeks
Vaccinated 2 weeks . . .
Infected 1 week
Vaccinated 1 week
Saline controls
9/10
10/10
4/10
10/10
9/10
9/10
10/10
1/10
9/10
5/10
7/10
1/10
9/10
6/10
1/10
5/10
1/10
1/10
0/10
5/10
1/10
1/10
1/10
1/10
0/10
0/10
0/10
0/10
0/10
1/10
0/10
0/10
0/10
0/10
0/10
Numerator indicates number of deaths.
Denominator indicates number challenged.
TABLE 7
Deaths of mice receiving high titered antiserum to
S. schenckii from rabbits or serum from
infected mice, after challenge
Source of Serum
Challenging Dose
3.5 >(
10'
3.5 X
10'
3.5 X
10
3.5 X
10'
3.5 X
10'
Infected mice
Normal mice
Immune rabbits
Normal rabbits
Saline controls
5/5
5/5
5/5
5/5
5/5
5/5
5/5
4/5
5/5
5/5
4/5
0/5
3/5
1/5
4/5
0/5
0/5
1/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
fungus in cultures from the autopsied animals.
Table 3 shows more survivors in the control
group than in the group receiving acetone-
treated cells, but the difference is very small.
DISCUSSION
It is apparent from the studies presented here
that the protection in mice against sporotrichosis
due to vaccination with formalin-treated vaccines
or preinfection is of a low degree. Furthermore,
considering the methods used to date, it is prob-
ably unrealistic to employ the high level of
immunity that can be produced to certain bac-
terial or viral diseases as a base line, when equat-
ing artificially induced resistance to the deep-
seated mycoses.
Vaccine
Challenging Dose
Numerator indicates number of deaths; de-
nominator indicates number challenged.
* Experiment terminated 6 weeks after chal-
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Friedman and Smith (1) have shown that
killed arthrospores of Coccidioldes immitis pro -
teeted mice against lethal doses of viable arthro-
spores, but that the survivors were infected.
Studies by Vogel, et at. (2), using C. immitis
spherules cultured from chick embryos for sensi-
tizing guinea pigs, indicated that less extensive
disease was observed in the test animals than in
the controls. Investigating artificially acquired
immunity to histoplasmosis in mice, Salvin (4)
reported a high level of protection by immunizing
with formalin-killed acetone dried Histoplasina
caps ulatum yeast cells. Rowley and Huber (3),
using a different strain of H. capsulatum, were
unable to confirm Salvin's results, but presented
evidence that preinfected mice were more resis-
tant to challenge than the controls. Later work
by Salvin (8) indicated that H. capsulatum did
not multiply in the tissues of immunized mice
at the same rate as in the controls. The course
of histoplasmosis (3) in mice was not noticeably
altered or modified by the injection of immune
serum. Our studies with sporotrichosis gave
similar results.
The investigation presented here is in accord
with that of Jessner (6) who was studying cu-
taneous reinfection with sporotrichosis.
The onset of the deep-seated mycoses may be
insidious, and they are chronic diseases under
most circumstances. It is quite obvious that the
laboratory induced resistance to these mycoses
does not measure up to the classic immunological
criteria applied to many other host-parasite rela-
tionships. However, it is logical to consider that
the subtle differences of resistance demonstrated
by this and other studies derived from relatively
short-term experiments, may not illustrate the
true importance of even a low level of immunity.
This partial immunity may prove to be more
significant when extended over longer periods of
time.
SUMMARY
Evidence of slight protection of mice against
sporotrichosis following immunization with
formalin-killed suspensions of Sporotrichum
schenclcii, or preinfection has been presented.
Attempts at passive immunization, with serum
from rabbits immunized against 8. .schenc/cii or
with serum from infected mice, did not modify
the course of the infection.
Interpretation of the results was based on sur-
vivor numbers, since all animals were still in-
fected at the end of the experimental period.
A discussion of the possible value of the rela-
tively low level of immunity in this, and in
reported studies of other systemic mycoses, is
presented.
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